Renaissance Technologies (RenTech)'s TSHA Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 413,203 shares of Taysha Gene Therapies, Inc. (TSHA) worth $1.85 M, representing 0.00% of the portfolio. First purchased in 2022-Q1, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in TSHA, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 878,448 shares. Largest reduction occurred in Q1 2025, reducing 878,448 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Taysha Gene Therapies (TSHA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Taysha Gene Therapies (TSHA) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +242,103 | Add 141.50% | 413,203 | $4.47 |
| Q4 2025 | +171,100 | New Buy | 171,100 | $5.50 |
| Q3 2025 | -54,900 | Sold Out | 0 | $0.00 |
| Q2 2025 | +54,900 | New Buy | 54,900 | $2.31 |
| Q1 2025 | -878,448 | Sold Out | 0 | $0.00 |
| Q4 2024 | +878,448 | New Buy | 878,448 | $1.73 |
| Q3 2024 | -41,100 | Sold Out | 0 | $0.00 |
| Q2 2024 | -287,400 | Reduce 87.49% | 41,100 | $2.24 |
| Q1 2024 | -768,900 | Reduce 70.07% | 328,500 | $2.87 |
| Q4 2023 | +499,400 | Add 83.51% | 1.1 M | $1.77 |
| Q3 2023 | +373,600 | Add 166.49% | 598,000 | $3.16 |
| Q2 2023 | -25,200 | Reduce 10.10% | 224,400 | $0.00 |
| Q1 2023 | -270,200 | Reduce 51.98% | 249,600 | $0.00 |
| Q4 2022 | +101,300 | Add 24.21% | 519,800 | $0.00 |
| Q3 2022 | -105,100 | Reduce 20.07% | 418,500 | $1.93 |
| Q2 2022 | +273,100 | Add 109.02% | 523,600 | $3.72 |
| Q1 2022 | +250,500 | New Buy | 250,500 | $6.52 |
Renaissance Technologies (RenTech)'s Taysha Gene Therapies Investment FAQs
Renaissance Technologies (RenTech) first purchased Taysha Gene Therapies, Inc. (TSHA) in Q1 2022, acquiring 250,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Taysha Gene Therapies, Inc. (TSHA) for 17 quarters since Q1 2022.
Renaissance Technologies (RenTech)'s largest addition to Taysha Gene Therapies, Inc. (TSHA) was in Q4 2024, adding 878,448 shares worth $1.52 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 413,203 shares of Taysha Gene Therapies, Inc. (TSHA), valued at approximately $1.85 M.
As of the Q1 2026 filing, Taysha Gene Therapies, Inc. (TSHA) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Taysha Gene Therapies, Inc. (TSHA) was 1,097,400 shares, as reported at the end of Q4 2023.